Prathibha Shetty | Head, Regenerative Medicine Group
Reliance Life Sciences | India

Prathibha Shetty, Head, Regenerative Medicine Group, Reliance Life Sciences

Dr. Prathibha Shetty completed her post-graduation (Masters in Science) from Mumbai University in 1997 with the specialization in Microbiology. After post-graduation she joined Reliance Life Sciences in the year 2001, where she completed her doctoral degree from Mumbai University in 2010 with the specialization in Stem Cells. She is one of the pioneer members to have been awarded the doctoral degree in the area of stem cells. Currently, she is heading the Regenerative Medicine group with 17 years of enriched experience with the adult stem cells. She has a total of 20 years of experience in the field of Biotechnology.

She is an active member in various committees involved in important decision makings. She is invited as a Stem cell expert in the Scientific Advisory Committee of the Surat Rakthdan Kendra, Surat. Invited as an external examiner for biotechnology courses (B Tech and M Tech). She is member of the institutional Biosafety committee at Reliance Life Sciences. Also a member of the thesis advisory committee to NMIMS, Mumbai. 
She have several international and national publications to her credit. Also has few patents in the area of stem cells. She attends and makes presentation in various international and national conferences.

Her core area is Research and Development involving Stem Cells exploring their potential for various unmet medical needs. Her expertise involves studying the stem cell differentiation from various adult sources and proving their safety and efficacy in diseased animal models. Further, upon proving the safety and efficacy of these cells in preclinical studies leading to the IND (regulatory) applications for conducting human clinical trials. Spinal cord injury, Parkinson’s disease, Peripheral vascular disease, Renal disorders (Acute and Chronic) are some of the degenerative disorders which have been covered in the various IND applications applied so far. The phase I clinical trials using the autologous mesenchymal stem cells for Spinal cord injury and Parkinson’s disease has been successfully completed proving these cells to be safe and efficacious for neurological applications. Clinical trial studies using the allogeneic mesenchymal stem cells for Type1 Diabetes mellitus, Graft Versus Host disease and Ischemic Limb disease are currently ongoing.

Appearances:



Phar-East Day Two @ 15:15

Case study: What it takes to achieve commercial success for cell & gene therapy products

The uphill path towards commercial success of cell & gene therapy is costly and time extensive. So how do we get there?

back to speakers